Spotlight
Center of Excellence for Myelodysplastic Syndromes (MDS)
ÍÑÒÂÖ±²¥ is recognized as a Center of Excellence by the Myelodysplastic Syndrome (MDS) Foundation for its MDS expertise and research.
As a Center of Excellence for MDS and myeloproliferative neoplasms, Rush offers advanced, personalized care for these rare blood and bone marrow disorders.
ÍÑÒÂÖ±²¥ is recognized as a Center of Excellence by the Myelodysplastic Syndrome (MDS) Foundation for its MDS expertise and research.
Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms are rare stem cell disorders. Though these are rare diseases, you’ll find nationally renowned experts at Rush who have spent decades caring for people who have these conditions.
Our care team at Rush is dedicated to patient-focused care. That means we’ll evaluate your condition and discuss your treatment options with you. From there, we'll develop a care plan tailored to your specific symptoms, needs, lifestyle and concerns. You will also have a nurse navigator who will help coordinate your care every step of the way.
Your treatment plan may include a wide variety of standard treatment options for myelodysplastic syndromes and myeloproliferative neoplasms, including stem cell transplantation. And, you’ll also have access to cutting edge clinical trials that are looking at novel approaches for treating these conditions.
Rush has myelodysplastic syndromes (MDS) myeloproliferative neoplasms providers in Chicago and Lisle.
U.S. News & World Report ranked ÍÑÒÂÖ±²¥ among the best in the nation for cancer care.
Researchers at Rush are investigating new blood disorders and hematologic cancer treatments.
1520 W Harrison St
Joan and Paul Rubschlager Building
Chicago, IL 60607
The new Joan and Paul Rubschlager Building is a destination for state-of-the-art outpatient care in cancer, neurosciences, digestive diseases and more. Read stories that highlight what Rush means to its patients, providers, employees and community — and illustrate how the Rubschlager Building is supporting Rush in providing excellent patient care, in 2023 and beyond.
Read Their Stories